This data contains popular baby names in New York .

Dataset :- 1 file (popular-baby-names.csv)

Columns - Year of Birth : Year of the baby's birth. - Gender : Gender of the baby. - Ethnicity : Types of ethnicity they belong to. - Child's First Name : The first name of the child. - Count : How many babies were named . - Ranking : Ranking of that name.

This data package consists of 26 datasets all containing statistical data relating to the population and particular groups within it belonging to different countries, mostly the United States.

Importance: Serosurveys can be used to monitor population-level dynamics of COVID-19 and vaccination. Dried blood spots (DBSs) collected from infants contain maternal IgG antibodies and are useful for serosurveys of individuals recently giving birth. Objectives: To examine SARS-CoV-2 antibody prevalence in pregnant individuals in New York State, identify associations between SARS-CoV-2 antibody status and maternal and infant characteristics, and detect COVID-19 vaccination among this population. Design, setting, and participants: A population-based, repeated cross-sectional study was conducted to detect SARS-CoV-2 nucleocapsid (N) and spike (S) IgG antibodies. Deidentified DBS samples and data submitted to the New York State Newborn Screening Program between November 1, 2019, and November 30, 2021, were analyzed. Exposures: Prenatal exposure to SARS-CoV-2 antibodies. Main outcomes and measures: The presence of IgG antibodies to SARS-CoV-2 N and S antigens was measured using a microsphere immunoassay. Data were analyzed by geographic region and compared with reported COVID-19 cases and vaccinations among reproductive-aged females (15-44 years of age). Data were stratified by infant birth weight, gestational age, maternal age, and multiple birth status. Results: Dried blood spot samples from 415 293 infants (median [IQR] age, 1.04 [1.00-1.20] days; 210 805 [51.1%] male) were analyzed for SARS-CoV-2 antibodies. The first known antibody-positive infant in New York State was born on March 29, 2020. SARS-CoV-2 seroprevalence reflected statewide and regional COVID-19 cases among reproductive-aged females in the prevaccine period. From February through November 2021, S seroprevalence was strongly correlated with cumulative vaccinations in each New York State region and in the state overall (rs = 0.92-1.00, P ≤ .001). S and N seroprevalences were significantly lower in newborns with very low birth weight (720 [14.8%] for S and 138 [2.8%] for N, P < .001) and low birth weight (5160 [19.3%] for S and 1233 [4.6%] for N, P = .009) compared with newborns with normal birth weight (77 116 [20.1%] for S and 19 872 [5.2%] for N). Lower N and higher S seroprevalences were observed in multiple births (odds ratio [OR], 0.84; 95% CI, 0.75-0.94; P = .002 for N and OR, 1.24; 95% CI, 1.18-1.31; P < .001 for S) vs single births and for maternal age older than 30 years (OR, 0.87; 95% CI, 0.80-0.94; P < .001 for N and OR, 1.17; 95% CI, 1.11-1.23; P < .001 for S) vs younger than 20 years. Conclusions and relevance: In this study, seroprevalence in newborn DBS samples reflected COVID-19 case fluctuations and vaccinations among reproductive-aged women during the study period. These results demonstrate the utility of using newborn DBS testing to estimate SARS-CoV-2 seroprevalence in pregnant individuals.

This collection contains five modified data sets with mortality, population, and other demographic information for five American cities (Baltimore, Maryland; Boston, Massachusetts; New Orleans, Louisiana; New York City (Manhattan only), New York; and Philadelphia, Pennsylvania) from the early 19th century to the early 20th century. Mortality was represented by an annual crude death rate (deaths per 1000 population per year). The population was linearly interpolated from U.S. Census data and state census data (for Boston and New York City). All data sets include variables for year, total deaths, census populations, estimated annual linearly interpolated populations, and crude death rate. The Baltimore data set (DS0001) also provides birth and death rate variables based on race and slave status demographics, as well as a variable for stillbirths. The Philadelphia data set (DS0005) also includes variables for total births, total infant deaths, crude birth rate, and infant deaths per 1,000 live births.

The United States senior living market, valued at $112.93 billion in 2025, is experiencing robust growth, projected to expand at a Compound Annual Growth Rate (CAGR) of 5.86% from 2025 to 2033. This expansion is fueled by several key drivers. The aging population, particularly the baby boomer generation, is a significant factor, creating an increasing demand for assisted living, independent living, memory care, and nursing care facilities. Furthermore, rising disposable incomes and increasing awareness of the benefits of senior living communities contribute to market growth. Technological advancements in senior care, such as telehealth and remote monitoring, are also enhancing the quality of life for residents and boosting market appeal. However, the market faces some restraints, including the rising costs of healthcare and senior care services, potentially limiting accessibility for some segments of the population. Furthermore, staffing shortages within the industry represent a significant challenge. The market is segmented by property type, with assisted living, independent living, and memory care facilities representing the largest segments. Key states driving market growth include New York, Illinois, California, North Carolina, and Washington, reflecting higher concentrations of the senior population and higher disposable incomes. Major players in the market such as Ensign Group Inc, Sunrise Senior Living, Brookdale Senior Living Inc, and Atria Senior Living Inc, compete fiercely, driving innovation and service improvements. The forecast period (2025-2033) anticipates continued growth, driven by the ongoing demographic shifts and increased demand for high-quality senior care options. Strategic partnerships, acquisitions, and investments in technology are likely to shape the competitive landscape in the coming years. The industry will continue to adapt to meet the evolving needs of the aging population, focusing on personalized care, innovative technologies, and cost-effective solutions. This comprehensive report provides an in-depth analysis of the booming United States senior living market, covering the period from 2019 to 2033. With a base year of 2025 and a forecast period spanning 2025-2033, this report is an invaluable resource for investors, industry professionals, and anyone seeking to understand the dynamics of this rapidly evolving sector. The report leverages extensive data analysis to provide insightful projections and uncover key trends shaping the future of senior care in the US. Expect detailed breakdowns of key segments, including assisted living, independent living, memory care, and nursing care, across major states like California, New York, Illinois, North Carolina, and Washington. Recent developments include: July 2023: Spring Cypress senior living site expansion is set to open at the end of 2024 and will consist of three phases. The first phase of the expansion will include 19 independent-living, two-bedroom cottages. The second phase will include 24 townhomes. The third phase will feature 95 apartments. The final phase will feature a resort with several luxury amenities., Apr 2023: For seniors looking for innovative, high-quality care, Avista Senior Living is transitioning away from its SafelyYou partnership to empower safer, more personalized dementia care with real-time, AI video and remote clinical experts 24/7.. Key drivers for this market are: 4., Increase in Aging Population Driving the Market4.; Healthcare and Long-term Care Needs Driving the Market. Potential restraints include: 4., High Affordability and Cost of Care Affecting the Market4.; Staffing and Workforce Challenges Affecting the Market. Notable trends are: Senior Housing Witnessing Increased Demand.